just be campaign top just be campaign bottom
mobile - delayed CINV shouldn't define her

Because delayed CINV shouldn’t define her.

See the defining features of VARUBI   button arrow

Indication: VARUBI® (rolapitant), in combination with other antiemetic agents, is indicated in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Contraindication: VARUBI is contraindicated in patients receiving thioridazine, a CYP2D6 substrate. A significant increase in plasma concentrations of thioridazine may result in QT prolongation and Torsades de Pointes.

CINV, chemotherapy-induced nausea and vomiting.

scroll indicator arrow

Despite antiemetic treatment,

More than half are still suffering1

mobile - more than half are still suffering

The numbers will surprise you   button arrow

The majority of patients undergoing highly or moderately emetogenic chemotherapy (HEC or MEC) experience delayed chemotherapy-induced nausea and vomiting (CINV)—even when prescribed a 5-hydroxytryptamine-3 (serotonin) receptor antagonist (5-HT3 RA) and a corticosteroid.1

scroll indicator arrow
floating nurse image

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis recognizes

The need for prevention of delayed CINV2

mobile - the need for prevention of delayed CINV

Learn more about adding an NK-1 RA   button arrow

scroll indicator arrow

VARUBI® (rolapitant) as part of an antiemetic regimen:

Proven protection with one dose3

mobile - proven protection with one dose

Discover how your patients may benefit   button arrow

Warnings and precautions

Interaction with CYP2D6 substrates with a narrow therapeutic index

  • The inhibitory effect of VARUBI on CYP2D6 lasts for at least 7 days and may last longer after administration of a single dose of VARUBI
  • Avoid use of VARUBI in patients who are receiving pimozide, a CYP2D6 substrate. An increase in plasma concentrations of pimozide may result in QT prolongation
  • Monitor for adverse reactions if concomitant use of VARUBI and other CYP2D6 substrates with a narrow therapeutic index cannot be avoided

scroll indicator arrow

varubi logo - color varubi logo - white
Indication and Important Safety Information for VARUBI® (rolapitant)   button arrow